Category Regulatory

Jazz Pharma Gains FDA Approval for Ziihera® to Treat Advanced HER2+ Biliary Tract Cancer

Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL injection. This intravenous treatment is for adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC). Approval…

Read MoreJazz Pharma Gains FDA Approval for Ziihera® to Treat Advanced HER2+ Biliary Tract Cancer

Extended Data Confirms Acoramidis Sustains Cardiovascular Benefits, Reduces ACM at 36 Months

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced positive interim results from the ATTRibute-CM open-label extension (OLE) study of acoramidis, presented at the American Heart Association (AHA) Scientific Sessions. Acoramidis, an investigational small molecule…

Read MoreExtended Data Confirms Acoramidis Sustains Cardiovascular Benefits, Reduces ACM at 36 Months

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV…

Read MoreGilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Exelixis Reports Q3 2024 Financial Results and Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) released its third-quarter financial results for 2024 and highlighted recent progress across key commercial, clinical, and pipeline milestones. Key Developments and Corporate Updates Pipeline and Clinical Trials Cabozantinib Franchise Revenue: The cabozantinib franchise generated $478.1 million…

Read MoreExelixis Reports Q3 2024 Financial Results and Corporate Update

Dr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row

Dr. Reddy’s Laboratories Ltd. has been recognized as one of the top employers in the 2024 Top Biotech and Pharma Employers Survey conducted by Science magazine, marking the company’s third consecutive year on the prestigious list. In the 2022 survey,…

Read MoreDr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row